cholesterollowering agents (e.g., statins, bile acid sequestrants, nicotinic acid agents, etc.) to fenofibrate despite its urate-lowering effects 8 5 http:// onlinelibrary.wiley.com/doi/10.1002/acr.24180/abstract DISCUSSION These guidelines reinforce the strategy of starting with lowdose ULT and titrating up to achieve the SU target. This strategy mitigates the risk of treatment-related adverse effects (e.g., hypersensitivity) as well as flare risk accompanying ULT initiation In contrast to the